Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013-2019.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
06 2022
Historique:
revised: 07 02 2022
received: 28 10 2021
accepted: 03 03 2022
pubmed: 25 3 2022
medline: 6 5 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

We aim to report trends in unplanned hospitalizations among newly diagnosed heart failure patients with regard to hospitalizations types and their impact on outcomes. A nation-wide study of all citizens in Poland with newly diagnosed heart failure based on ICD-10 coding who were beneficiaries of either public primary, secondary, or hospital care between 2013 and 2018 in Poland. Between 1 January 2013 and 31 December 2019, there were 1 124 118 newly diagnosed heart failure patients in Poland in both out- and inpatient settings. The median observation time was 946 days. As many as 49% experienced at least one acute heart failure hospitalization. Once hospitalized, 44.6% patients experienced at least one all-cause rehospitalization and 26% another heart failure rehospitalization. The latter had the highest Charlson co-morbidity index (1.36). The 30 day heart failure readmission rate was 2.96%. Kaplan-Meier analysis revealed very early readmissions (up to 1-7 days) were associated with better survival compared with rehospitalization between 8 and 30 days. All-cause mortality was related to the number of hospitalization with adjusted estimated hazard ratios: 1.550 (95% CI: 1.52-158) for the second HF hospitalization, 2.158 (95% CI: 2.098-2.219) for third, and 2.788 (95% CI: 2.67-2.91) for the fourth HF hospitalization and subsequent ones, as compared with the first hospitalization. Among newly diagnosed heart failure patients in Poland between 2013 and 2019, nearly half required at least one unplanned heart failure hospitalization. The risk of death was growing with every other hospital reoccurrence due to heart failure.

Identifiants

pubmed: 35322601
doi: 10.1002/ehf2.13900
pmc: PMC9065864
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1553-1563

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

JACC Heart Fail. 2021 May;9(5):349-359
pubmed: 33839078
Nat Rev Cardiol. 2016 Jun;13(6):368-78
pubmed: 26935038
Circ Heart Fail. 2018 Jun;11(6):e004646
pubmed: 29793934
Eur J Prev Cardiol. 2018 Jun;25(9):960-969
pubmed: 29692221
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Mayo Clin Proc. 2017 Feb;92(2):184-192
pubmed: 28160871
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
J Am Coll Cardiol. 2013 Jan 29;61(4):391-403
pubmed: 23219302
J Gen Intern Med. 2017 Oct;32(10):1097-1105
pubmed: 28685482
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292
Risk Manag Healthc Policy. 2017 May 10;10:63-70
pubmed: 28546776
ESC Heart Fail. 2021 Apr;8(2):1388-1397
pubmed: 33599109
Am J Med. 2009 Feb;122(2):162-169.e1
pubmed: 19100960
ESC Heart Fail. 2022 Jun;9(3):1553-1563
pubmed: 35322601
Am J Cardiol. 2019 Jun 1;123(11):1840-1844
pubmed: 30928031
J Am Coll Cardiol. 2021 May 11;77(18):2307-2319
pubmed: 33958128
Eur J Heart Fail. 2020 Feb;22(2):241-248
pubmed: 31646725
Arch Intern Med. 2002 Aug 12-26;162(15):1689-94
pubmed: 12153371
Circ Heart Fail. 2014 Nov;7(6):895-902
pubmed: 25326006
Eur J Heart Fail. 2016 Jun;18(6):613-25
pubmed: 27324686
N Engl J Med. 2010 Jul 15;363(3):297-8
pubmed: 20647209
ESC Heart Fail. 2020 Oct 22;:
pubmed: 33089965
Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):548-57
pubmed: 20031892
ESC Heart Fail. 2020 Aug;7(4):1688-1699
pubmed: 32383551
Mil Med. 2017 Sep;182(9):e1932-e1937
pubmed: 28885958
BMC Cardiovasc Disord. 2018 May 2;18(1):74
pubmed: 29716540
Eur J Heart Fail. 2021 Mar;23(3):420-431
pubmed: 33443295

Auteurs

Przemysław Leszek (P)

Department of Heart Failure and Transplantology, National Institute of Cardiology, Warsaw, Poland.

Daniel Waś (D)

Department of Analysis and Strategy, Ministry of Health, Warsaw, Poland.

Kinga Bartolik (K)

Department of Analysis and Strategy, Ministry of Health, Warsaw, Poland.

Kladiusz Witczak (K)

Department of Analysis and Strategy, Ministry of Health, Warsaw, Poland.

Andrzej Kleinork (A)

Cardiac Unit, Pope John Paul II Regional Hospital; Academy of Zamość, Zamość, Poland.
Academy of Zamość, Institute of Humanities and Medicine, Zamość, Poland.

Bohdan Maruszewski (B)

Pediatric Cardiothoracic Surgery Unit, The Children's Memorial Health Institute, Warsaw, Poland.

Katarzyna Brukało (K)

Department of Health Policy School of Health Sciences in Bytom, Medical University of Silesia, Katowice, Poland.

Paulina Rolska-Wójcik (P)

IQVIA, Warsaw, Poland.

Małgorzata Celińska-Spodar (M)

Department of Anesthesiology and Intensive Care, National Institute of Cardiology, Warsaw, Poland.

Tomasz Hryniewiecki (T)

Department of Valvular Heart Disease, National Institute of Cardiology, Warsaw, Poland.

Marta Załęska-Kocięcka (M)

Department of Anesthesiology and Intensive Care, National Institute of Cardiology, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH